Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal Carcinoma

This study tests whether adding targeted radiation (SBRT) to an ongoing immunotherapy and chemotherapy maintenance regimen improves outcomes in people with metastatic nasopharyngeal carcinoma (a type of head and neck cancer) that has responded to initial treatment. **You may be eligible if...** - You are between 18 and 70 years old - You have been diagnosed with nasopharyngeal carcinoma confirmed by biopsy or lab test - Your cancer has spread (metastatic) and you have had 4–6 cycles of gemcitabine + cisplatin + PD-1 immunotherapy with at least stable disease - You have fewer than 5 distant organ metastases, and they are suitable for targeted radiation - You are in good general health (ECOG score 0–2) - Your blood counts, kidney, and liver function are within acceptable ranges **You may NOT be eligible if...** - You have more than 5 distant organ metastases - Your cancer progressed during initial treatment - You have serious heart, liver, or kidney problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.